Acorda Therapeutics (ACOR) is in a better position after addressing the convertible note overhang last year. In my previous article, I noted the company is uninvestable due to this substantial financing overhang as the company lacked the cash to pay the noteholders in 2021 and the conversion price was far out of reach. The way the issue was addressed has caused potentially significant dilution, but it's better than the alternative. The crisis is now postponed and Acorda is currently in decent financial shape and management can focus on getting Inbrija sales to